ARK Investment Management also increased its exposure to companies including Block (), Verve Therapeutics (), Intellia Therapeutics (

Source: https://seekingalpha.com/article/4617275-analyzing-13fs-ark-investment-management-cathie-wood-q2-2023?source=feed_all_articles

Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a report on Tuesday, August 29th.

Source: https://www.dailypolitical.com/2023/09/05/intellia-therapeutics-inc-nasdaqntla-holdings-raised-by-wellington-management-group-llp.html

Citigroup Inc. trimmed its stake in Intellia Therapeutics, Inc. () by 15.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission.

Source: https://www.etfdailynews.com/2023/05/23/citigroup-inc-has-3-46-million-stake-in-intellia-therapeutics-inc-nasdaqntla/

Finally, Arizona State Retirement System boosted its position in Intellia Therapeutics by 4.0% during the fourth quarter.

Source: https://www.etfdailynews.com/2023/05/23/citigroup-inc-has-3-46-million-stake-in-intellia-therapeutics-inc-nasdaqntla/

Finally, Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $111.00 to $107.00 in a research note on Tuesday, June 13th.

Source: https://www.etfdailynews.com/2023/08/10/canaccord-genuity-group-trims-intellia-therapeutics-nasdaqntla-target-price-to-65-00/

Intellia Therapeutics ( genome editing company, striving to develop curative therapies using CRISPR-based technologies.

Source: https://seekingalpha.com/article/4585435-intellia-therapeutics-stock-progressing-pipeline-signals-positive-outlook-investors?source=feed_all_articles

On average, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.64 EPS for the current fiscal year.

Source: https://www.americanbankingnews.com/2023/11/12/allspring-global-investments-holdings-llc-acquires-3393-shares-of-intellia-therapeutics-inc-nasdaqntla.html